Is Arcus Biosciences (RCUS) stock Halal?

Arcus Biosciences is a biopharmaceutical company dedicated to developing innovative cancer therapies. Focusing primarily on immuno-oncology, the company aims to harness the body's own immune system to target and eliminate cancer cells. Arcus Biosciences' pipeline includes a variety of monoclonal antibodies, small molecules, and combination therapies that address different aspects of cancer's complex biology. Before any of that matters to a Muslim investor, one question comes first: is Arcus Biosciences stock Halal?

Is Arcus Biosciences Shariah compliant?

Yes. In the October 2026 screening Arcus Biosciences (RCUS) passes AAOIFI Shariah Standard No. 21: the business activity screen and every financial ratio screen hold. The Shariah case on a technology company like Arcus Biosciences is rarely about the product. What AAOIFI Shariah Standard No. 21 examines is the money around the product: cash parked in instruments that earn Riba, borrowing measured against a market capitalisation that moves daily, and any incidental income from sources Islam prohibits, which must stay below 5% of revenue.

Does Arcus Biosciences pass the business activity test?

Yes. In the October 2026 screening Arcus Biosciences holds an overall PASS, which a stock only earns when its core business clears the activity screen. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.

Is Arcus Biosciences' income Halal?

Yes, within AAOIFI's tolerance. Arcus Biosciences' income from non-permissible sources stays below 5% of revenue in the October 2026 screening, and the small impure portion is handled through purification: the factor of 100% tells holders of RCUS what share of each dividend to keep and what remainder to donate to charity. On a dividend yield of around None, the purification amount is modest but real.

Does Arcus Biosciences meet AAOIFI's debt and investment ratio requirements?

Yes. Both caps hold this month: interest bearing investments and interest bearing debt each stay below 30% of market capitalisation, measured against a market capitalisation of $3.29B (market data as of 1 October 2026). Because the caps move with the share price, our Shariah Supervisory Board has RCUS re-screened every month, and the result above always shows the latest verdict.

Why do other halal screeners show a different verdict for Arcus Biosciences?

Screeners can disagree without either being wrong. AAOIFI Shariah Standard No. 21, which Tabadulat applies, measures interest bearing debt and investments against market capitalisation with a 30% ceiling. MSCI and FTSE measure them against total assets with a 33% ceiling, and S&P and Dow Jones Islamic use a multi year average of market capitalisation. Data dates differ too, because each provider reads filings and prices on its own schedule. The same company can therefore pass one standard and fail another in the same month. Tabadulat publishes one answer, the AAOIFI result as of October 2026, and re-screens it every month.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the screening method? Read Why a Halal Stock Screener Matters for Halal Investing